STOCK TITAN

PepGen (PEPG) Stock Price, News & Analysis

PEPG NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
75 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
+92.9% close of November 10, 2026
1-year change
-25.7% closing prices, November 20, 2025 to November 20, 2026
1-month change
+31.7% closing prices, October 20, 2026 to November 20, 2026

Company Description

PepGen Inc. (Nasdaq: PEPG) is a clinical-stage biotechnology company focused on developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. The company is classified under pharmaceutical preparation manufacturing and operates in the broader manufacturing sector. According to its public disclosures, PepGen is advancing a proprietary Enhanced Delivery Oligonucleotide (EDO) platform that is intended to improve how oligonucleotide therapeutics reach and act within target tissues.

PepGen describes its EDO platform as being founded on over a decade of research and development and based on cell-penetrating peptides designed to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, the company is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases, particularly in neuromuscular and neurological indications.

Core technology and EDO platform

The company’s Enhanced Delivery Oligonucleotide technology leverages cell-penetrating peptides to support tissue penetration and cellular uptake of oligonucleotide drug candidates. In its public descriptions, PepGen highlights the goal of improving delivery of therapeutic oligonucleotides into relevant tissues for neuromuscular and neurological conditions. The platform underpins multiple investigational programs, including candidates for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy amenable to exon 51 skipping.

According to PepGen, the EDO platform is used to deliver therapeutic oligonucleotides that are designed to address disease mechanisms at the RNA level. The company reports that its approach aims to reach tissues such as skeletal muscle and other systems affected in neuromuscular disease, with the intention of correcting underlying molecular defects rather than only treating symptoms.

Key pipeline programs

PepGen’s disclosures describe a pipeline of oligonucleotide therapeutic candidates built on its EDO platform. These include:

  • PGN-EDODM1 – an investigational candidate in development for the treatment of myotonic dystrophy type 1 (DM1). PepGen states that PGN-EDODM1 utilizes its proprietary EDO technology to deliver a therapeutic oligonucleotide designed to restore the normal splicing function of MBNL1, a key RNA splicing protein. The company explains that PGN-EDODM1 is intended to address the deleterious effects of cytosine-uracil-guanine (CUG) repeat expansion in dystrophia myotonic(a) protein kinase (DMPK) transcripts, which sequester MBNL1. By binding to the pathogenic CUG trinucleotide repeat expansion and disrupting the binding between this expansion and MBNL1, the candidate is designed to liberate MBNL1 to correct downstream mis-splicing events while allowing DMPK transcripts to continue their normal function.
  • PepGen notes that the U.S. Food and Drug Administration has granted PGN-EDODM1 both Orphan Drug and Fast Track designations for the treatment of patients with DM1.
  • The company also references additional EDO-based candidates, including programs such as PGN-EDO51 and other EDO constructs, which are being evaluated in clinical and scientific settings for neuromuscular indications, including Duchenne muscular dystrophy amenable to exon 51 skipping.

Clinical development focus

PepGen describes itself as a clinical-stage company, indicating that its programs are in human trials rather than commercial use. For DM1, the company has reported data from the FREEDOM-DM1 Phase 1 single ascending dose study of PGN-EDODM1 in adults with myotonic dystrophy type 1. In that study, PepGen reported mean splicing correction at multiple dose levels and noted that PGN-EDODM1 was generally well tolerated at the doses evaluated, with drug-related adverse events characterized as mild or moderate in severity in its communications.

PepGen is also conducting FREEDOM2-DM1, a Phase 2 randomized, double-blind, placebo-controlled multiple ascending dose trial of PGN-EDODM1 in adult participants with DM1 in Canada, the United Kingdom and potentially other geographies, subject to regulatory clearances. An open-label extension study (PGN-EDODM1-OLE) has been cleared by the UK Medicines and Healthcare products Regulatory Agency and Health Canada, and PepGen states that participants from FREEDOM and FREEDOM2 will have the opportunity to enroll.

Target disease area: Myotonic dystrophy type 1 (DM1)

In its public materials, PepGen provides background on myotonic dystrophy type 1, describing it as a monogenic, autosomal dominant, progressive disorder that primarily affects skeletal, cardiac and smooth muscle, with central nervous system symptoms also evident. The company notes that DM1 patients can experience manifestations such as myotonia (temporary muscle rigidity due to inability to relax muscles), muscle weakness, cardiac abnormalities, respiratory problems, fatigue, gastrointestinal complications, early cataracts, and cognitive and behavioral impairments. For individuals with more severe forms of DM1, PepGen reports that life expectancy is reduced due to increased mortality related to pulmonary and cardiac complications.

PepGen positions PGN-EDODM1 as a candidate designed to address mis-splicing, which it describes as the underlying cause of DM1, by restoring normal splicing function rather than degrading DMPK transcripts. This mechanistic focus is central to the company’s rationale for its DM1 program.

Regulatory and capital markets context

PepGen’s common stock, with par value $0.0001 per share, is listed on the Nasdaq Global Select Market under the trading symbol PEPG, as disclosed in its SEC filings. The company has used the public equity markets to support its research and clinical development activities. For example, PepGen reported entering into an underwriting agreement to issue and sell shares of common stock pursuant to a shelf registration statement on Form S-3, and subsequently announced the closing of an underwritten public offering of common stock, with stated intentions to use the net proceeds to fund the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, as well as working capital and other general corporate purposes.

In addition, PepGen has reported the adoption and use of equity incentive plans, including a 2024 Inducement Plan, and has disclosed option repricing actions under its 2020, 2022 and 2024 equity plans. These disclosures emphasize the company’s use of equity-based compensation to retain and motivate employees during what it characterizes as a critical stage of its development.

Intellectual property and patent estate

PepGen has announced the issuance of a U.S. composition of matter patent covering PGN-EDODM1, which it describes as leveraging its proprietary EDO platform, including unique peptide and linker chemistry. The company characterizes this patent as a cornerstone of its expanding patent portfolio and notes that it complements a broader global patent estate that includes multiple issued and pending patents. According to PepGen, this patent is expected to provide exclusivity for PGN-EDODM1 in the United States into the second half of 2042, with the possibility of patent term extension following potential FDA approval.

Scientific and medical community engagement

PepGen reports that its data have been featured in oral presentations at scientific and medical conferences, including the International Congress of the World Muscle Society and meetings of the Oligonucleotide Therapeutics Society. These presentations have covered clinical data from the FREEDOM-DM1 Phase 1 study and results from clinical evaluation of PGN-EDO51 in Duchenne muscular dystrophy amenable to exon 51 skipping. Following such conferences, the company has indicated that presentation materials are made available under scientific publications on its website.

Risk and investigational status

Across its public communications, PepGen emphasizes that PGN-EDODM1 and its other oligonucleotide candidates are investigational therapies that have not been approved for use in any country. The company states that its press releases are not intended to convey conclusions about efficacy or safety and notes that there is no guarantee that PGN-EDODM1 or any other investigational therapy will successfully complete clinical development or obtain regulatory approval. This reflects the inherent uncertainty associated with clinical-stage biotechnology development.

Summary

Overall, PepGen Inc. presents itself as a Nasdaq-listed, clinical-stage biotechnology company focused on neuromuscular and neurological diseases through the development of oligonucleotide therapeutics enabled by its Enhanced Delivery Oligonucleotide platform. Its lead DM1 program, PGN-EDODM1, is supported by clinical data from the FREEDOM-DM1 study, ongoing evaluation in the FREEDOM2-DM1 trial, and U.S. regulatory designations intended for rare and serious conditions. Investors and observers considering PEPG stock often review the company’s platform description, pipeline status, patent estate, and regulatory and financing disclosures to understand its long-term development trajectory.

Stock Performance

$3.79
+0.26%
+0.01
After hoursChange vs the $3.78 closeLast updated: at
-25.7%
Performance 1 year
$357.2M

PepGen (PEPG) closed at $3.78 on November 20, 2026. Over the past 12 months, the price has lost 25.7%.

See what a $1,000 investment in PEPG would be worth today

Average down calculator for PEPG

PEPG Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

PepGen has 10 recent news articles. Of the recent coverage, 7 articles coincided with positive price movement and 3 with negative movement. Key topics include offering, earnings, clinical trial. View all PEPG news →

Insider Radar

Net Buyers
90-Day Summary
8,625,000
Shares Bought
0
Shares Sold
1
Transactions
Most Recent Transaction
RA Capital Healthcare Fund LP (Director) bought 8,625,000 shares held indirectly @ $5.00 on November 13, 2026

Insider buying activity at PepGen over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

PepGen reported operating income of -$93.6M in FY2025, and net income was -$89.7M. Diluted earnings per share stood at -$2.12. The company generated -$81.6M in operating cash flow. The current ratio was 11.94, measuring current assets divided by current liabilities.

-$89.7M
Net Income (FY2025)
-$81.6M
Operating Cash Flow
—
Revenue (FY2025)

Upcoming Events

DEC
08
December 8, 2026 Corporate

First option vesting

25% of 160,000-option vests (one-year anniversary of employment; grant 2025-12-08)
DEC
08
December 8, 2026 - December 8, 2029 Corporate

Monthly option vesting

Remaining 75% of option vests in equal monthly installments over next 3 years
DEC
11
December 11, 2026 Financial

Underwriters option expiry

30-day underwriter option to purchase up to 3,750,000 additional shares; option expected to expire Dec 11, 2026.
JAN
2027
January 2027 Clinical

Open-label interim data

Interim 5 mg/kg clinical data and 10 mg/kg safety data from the open-label extension expected in January 2027; may include webcast.
H1
2027
H1 2027 Clinical

12.5 mg/kg cohort results

Topline results expected for fully enrolled 12.5 mg/kg cohort; timing H1 2027; subject to U.S. partial clinical hold status.
JAN
2027
January 2027 Clinical

Extension study data

Extension-study data readout expected January 2027; will report splicing correction and functional measure outcomes.
H1
2027
H1 2027 Clinical

12.5 mg/kg results

Results expected for highest 12.5 mg/kg FREEDOM2 cohort in H1 2027; company plans end-of-Phase 2 regulatory meeting thereafter.
H1
2027
H1 2027 Clinical

OLE update

Open-label extension update expected by early January 2027; DSMB recommended escalation from 5 to 10 mg/kg, no SAEs reported.
H1
2027
H1 2027 Clinical

FREEDOM2 12.5 mg/kg Readout

Data from FREEDOM2 12.5 mg/kg dose cohort expected in 1H 2027; PepGen will provide timing, topline results and webcast details.
H2
2027
H2 2027 Regulatory

End-of-Phase 2 meeting

Planned end-of-Phase 2 meeting targeted for 2H 2027; scheduling contingent on removal of U.S. partial clinical hold.
DEC
08
December 8, 2035 Corporate

Option expiration

10-year term expiry of the non-qualified option (last day to exercise)
H2
2042
H2 2042 Regulatory

U.S. exclusivity into H2 2042

USPTO issued composition-of-matter patent extending U.S. exclusivity into H2 2042.

PepGen has 12 upcoming scheduled events. The next event, "First option vesting", is scheduled for December 8, 2026 (in 16 days). 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the PEPG stock price.

Short Interest History

Last 12 Months

Short interest in PepGen (PEPG) currently stands at 3.4 million shares, down 11.5% from the previous reporting period, representing 22.1% of the float. Since November 2025, short interest has increased by 46.3%.

Days to Cover History

Last 12 Months

Days to cover for PepGen (PEPG) currently stands at 2.8 days, down 46.7% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 29.8%. Across the settlements charted above, it has ranged from 1.2 to 9.4 days.

PEPG Company Profile & Sector Positioning

PepGen (PEPG) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing PEPG often look at related companies in the same sector, including Eupraxia Pharmaceuticals Inc. (EPRX), Contineum Therapeutics, Inc. (CTNM), Avalo Therapeutics, Inc. (AVTX), Opus Genetics, Inc. (IRD), and Rezolute, Inc. (RZLT). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate PEPG's relative position within its industry.

Frequently Asked Questions

The current stock price of PepGen (PEPG) is $3.79 in after-hours trading as of November 20, 2026.

The market cap of PepGen (PEPG) is approximately $357.2M. Learn more about what market capitalization means .

The FY2025 net income of PepGen (PEPG) is -$89.7M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of PepGen (PEPG) is -$2.12 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of PepGen (PEPG) is -$81.6M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of PepGen (PEPG), current assets divided by current liabilities, was 11.94 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of PepGen (PEPG) is -$93.6M for FY2025, its most recent completed fiscal year. Learn about operating income.

PepGen Inc. is a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. The company’s programs are built on its Enhanced Delivery Oligonucleotide (EDO) platform, which uses cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics.

PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, PepGen is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases, particularly in neuromuscular and neurological indications.

PGN-EDODM1 is PepGen’s investigational oligonucleotide candidate in development for the treatment of myotonic dystrophy type 1 (DM1). It utilizes the company’s proprietary EDO technology to deliver a therapeutic oligonucleotide designed to restore the normal splicing function of MBNL1, addressing the deleterious effects of CUG repeat expansion in DMPK transcripts that sequester MBNL1.

PepGen states that PGN-EDODM1 binds to the pathogenic CUG trinucleotide repeat expansion present in DMPK transcripts and disrupts the binding between this expansion and the MBNL1 protein. This approach is intended to liberate MBNL1 to correct downstream mis-splicing events while allowing DMPK transcripts to continue their normal function within the cell, addressing what the company describes as the underlying cause of DM1.

According to PepGen’s public disclosures, the U.S. Food and Drug Administration has granted PGN-EDODM1 both Orphan Drug and Fast Track designations for the treatment of patients with myotonic dystrophy type 1 (DM1). These designations are intended for therapies targeting serious or rare conditions and can provide certain regulatory advantages.

PepGen has reported conducting FREEDOM-DM1, a multinational, randomized, double-blind, placebo-controlled Phase 1 single ascending dose study of PGN-EDODM1 in adults with DM1, and FREEDOM2-DM1, a Phase 2 randomized, double-blind, placebo-controlled multiple ascending dose trial in approximately 24 adult participants with DM1 in Canada, the United Kingdom and potentially other geographies, subject to regulatory clearances. An open-label extension study, PGN-EDODM1-OLE, has also been cleared by regulators in the UK and Canada.

PepGen’s common stock, with par value $0.0001 per share, is listed on the Nasdaq Global Select Market under the trading symbol PEPG, as disclosed in the company’s SEC filings.

PepGen has disclosed that it uses proceeds from public offerings of its common stock to fund its research and clinical development efforts. For example, the company entered into an underwriting agreement to issue and sell shares under a shelf registration statement on Form S-3 and later announced the closing of an underwritten public offering, stating that net proceeds are intended to support the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, as well as working capital and other general corporate purposes.

PepGen has announced that the United States Patent and Trademark Office issued a composition of matter patent covering PGN-EDODM1, which leverages the company’s proprietary EDO platform, including its peptide and linker chemistry. The company describes this patent as a cornerstone of its expanding patent portfolio and notes that it complements a broader global patent estate with multiple issued and pending patents.

No. PepGen states that PGN-EDODM1 and its other oligonucleotide candidates are investigational therapies that have not been approved for use in any country. The company emphasizes that there is no guarantee that PGN-EDODM1 or any other investigational therapy will successfully complete clinical development or gain regulatory approval.